<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947595</url>
  </required_header>
  <id_info>
    <org_study_id>DZD-2012</org_study_id>
    <nct_id>NCT01947595</nct_id>
  </id_info>
  <brief_title>Individualized Lifestyle Intervention in Subjects With Prediabetes</brief_title>
  <acronym>PLIS</acronym>
  <official_title>Prediabetes Lifestyle Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Diabetes-Center, Leibniz-Institut in Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Endocrinology and Metabolic Diseases, Charité Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Institute of Human Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LMU München, medical clinic IV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized multicenter intervention study is to determine&#xD;
      whether in the prevention of Diabetes an intensified lifestyle intervention is superior to a&#xD;
      conventional lifestyle intervention in high risk non-Responder subjects. Further, the&#xD;
      intensive phenotyping to determine subgroups with an increased risk for diabetes enables an&#xD;
      individualized prevention and therapy of type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study start with an intensive phenotyping at baseline (initial examination) to determine&#xD;
      subjects with prediabetes. These high risk non-Responder are randomized in two arms&#xD;
      (intensified vs normal lifestyle intervention)with equal number of subjects (n=250). The&#xD;
      results are compared with each other at the end of the study.&#xD;
&#xD;
      The low risk Responder are randomized in two arms (normal vs. once lifestyle intervention =&#xD;
      control group) with equal number of subjects (n=250).&#xD;
&#xD;
      After the screening at baseline the 12 month lifestyle intervention starts for lifestyle&#xD;
      intervention groups. The different therapy groups are formed as described before. The&#xD;
      subjects with intensified lifestyle intervention get 16 consultations, the subjects with&#xD;
      normal lifestyle intervention get 8 consultations, the subjects of the control group get one&#xD;
      consultation to learn more about a healthier lifestyle. During the whole study there is a&#xD;
      continuous supervision from physician and nutritional advisers and the subjects have to&#xD;
      document a nutrition and an exercise protocol as well as subjective measurements. At&#xD;
      baseline, after 24 weeks and at follow up 1, 2 and 3 years later there is an elaborate&#xD;
      metabolic characterization of all subjects (also the Responder groups) a 75 g venous oral&#xD;
      glucose tolerance test (OGTT) as well as an analysis of the distribution of body fat&#xD;
      confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT))</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity confirmed by 75 g oral glucose tolerance test (OGTT)</measure>
    <time_frame>one year</time_frame>
    <description>insulin resistance is calculated as follows:&#xD;
Insulinogenic index (IGI) = (I30 - I0) / (G30 - G0)&#xD;
ISIest= 10000/²√ ((G0 x I0) x ((G0+G30+G60+G90+G120)/5) x ((I0+I30+I60+I90+I120)/5))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion confirmed by 75 g oral glucose tolerance test (OGTT)</measure>
    <time_frame>one year</time_frame>
    <description>insulin resistance is calculated as follows:&#xD;
Insulinogenic index (IGI) = (I30 - I0) / (G30 - G0)&#xD;
ISIest= 10000/²√ ((G0 x I0) x ((G0+G30+G60+G90+G120)/5) x ((I0+I30+I60+I90+I120)/5))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of body fat confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>metabolic and genetic characterization to determine the risk of type 2 diabetes confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires, bio-electric impedance analysis (BIA)and ergospirometry</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>metabolic and genetic characterization to determine the non-response to lifestyle intervention confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires,BIA, ergospirometry</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1145</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>high risk non-responder, intensified lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high risk non-responder:&#xD;
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)&#xD;
B) insulin resistance (ISI-Matsuda &lt; 9,2)&#xD;
C) elevated liver fat ( MRT &gt; 5,56%)&#xD;
A+B or A+C or B+C or A+B+C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hight risk non responder, normal lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high risk non-responder:&#xD;
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)&#xD;
B) insulin resistance (ISI-Matsuda &lt; 9,2)&#xD;
C) elevated liver fat ( MRT &gt; 5,56%)&#xD;
A+B or A+C or B+C or A+B+C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Responder, normal lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Responder:&#xD;
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)&#xD;
B) insulin resistance (ISI-Matsuda &lt; 9,2)&#xD;
C) elevated liver fat ( MRT &gt; 5,56%)&#xD;
No A, only B or C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Responder, single lifestyle advice (control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Responder:&#xD;
A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)&lt; 760)&#xD;
B) insulin resistance (ISI-Matsuda &lt; 9,2)&#xD;
C) elevated liver fat ( MRT &gt; 5,56%)&#xD;
No A, only B or C</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>intensified lifestyle intervention</intervention_name>
    <description>physical activity 6 hours per week, 50% guided activity&#xD;
recorded by an accelerometer (Aipermotion 440)&#xD;
16 sessions per year with a lifestyle advisor&#xD;
nutritional advice (target weight: 5% less, if BMI &gt; 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)</description>
    <arm_group_label>high risk non-responder, intensified lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>normal lifestyle intervention</intervention_name>
    <description>physical activity 3 hours per week&#xD;
recorded by an accelerometer (Aipermotion 440)&#xD;
8 sessions per year with a lifestyle advisor&#xD;
nutritional advice (target weight: 5% less, if BMI &gt; 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)</description>
    <arm_group_label>Responder, normal lifestyle intervention</arm_group_label>
    <arm_group_label>hight risk non responder, normal lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Single lifestyle advice</intervention_name>
    <description>- Single Health care advice and lifestyle advice (30 minutes) at the beginning&#xD;
recommend the individual target weight (5% less, if BMI 25&gt; kg/m²)</description>
    <arm_group_label>Responder, single lifestyle advice (control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  impaired fasting glucose (IFG)&#xD;
&#xD;
               -  fasting blood glucose 99-126 mg/dl&#xD;
&#xD;
        and/or&#xD;
&#xD;
          -  impaired glucose tolerance (IGT)&#xD;
&#xD;
               -  75 g OGTT 120 minutes: 139-200 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current pregnancy or breastfeeding&#xD;
&#xD;
          -  BMI &gt; 45 kg/m²&#xD;
&#xD;
          -  Diabetes mellitus Typ 1 or 2&#xD;
&#xD;
          -  serious disease e.g symptomatic coronary heart disease&#xD;
&#xD;
          -  serious symptomatic malignant disease (weight loss &gt; 10% within the last 6 month)&#xD;
&#xD;
          -  severe liver or kidney disease ( an increase in transaminases &gt; 3 times than the upper&#xD;
             limit of the standardized range, GFR &lt; 50 ml/min/1,73m²)&#xD;
&#xD;
          -  systemic infection (CRP &gt; 1 mg/dl)&#xD;
&#xD;
          -  severe mental illness&#xD;
&#xD;
          -  drug abuse&#xD;
&#xD;
          -  treatment with steroids&#xD;
&#xD;
          -  potentially incompliant subjects&#xD;
&#xD;
          -  exclusion criteria for magnetic resonance tomography&#xD;
&#xD;
               -  any kind of metal in or on the body:&#xD;
&#xD;
                    -  cardiac pacemakers&#xD;
&#xD;
                    -  prosthetic heart valves&#xD;
&#xD;
                    -  metal prosthesis&#xD;
&#xD;
                    -  magnetic implanted metallic parts&#xD;
&#xD;
                    -  contraceptive coil&#xD;
&#xD;
                    -  metal fragments/ grenade shrapnel&#xD;
&#xD;
                    -  fixed braces&#xD;
&#xD;
                    -  acupuncture needles&#xD;
&#xD;
                    -  insulin pump&#xD;
&#xD;
                    -  intraport etc.&#xD;
&#xD;
                    -  Field strength &gt; 3 Tesla further tattoos, permanent make-up&#xD;
&#xD;
               -  persons with limited thermosensory or heightened sensitivity to heating&#xD;
&#xD;
               -  persons where cardiovascular disease cannot be ruled out by examination&#xD;
&#xD;
               -  persons with heightened sensitivity to loud noise or diseases of the ear&#xD;
&#xD;
               -  used closed whole body scanner: claustrophobia&#xD;
&#xD;
        Additional for spirometry&#xD;
&#xD;
          -  acute coronary syndrome&#xD;
&#xD;
          -  higher cardiac arrhythmia&#xD;
&#xD;
          -  decompensated heart failure&#xD;
&#xD;
          -  acute carditis&#xD;
&#xD;
          -  pulmonary embolism&#xD;
&#xD;
          -  acute deep leg vein thrombosis ( phlebothrombosis)&#xD;
&#xD;
          -  hyperthyroidism (TSH)&#xD;
&#xD;
          -  hypokalemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Fritsche, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Stefan, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Institut für Ernährungsforschung / Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Diabetes Zentrum</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München (TU Munich)</name>
      <address>
        <city>Munich</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helmholtz Zentrum München</name>
      <address>
        <city>Munich</city>
        <zip>85764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dzd-ev.de</url>
    <description>Click here for more information about this study: research in the DZD --&gt; klinische Studien</description>
  </link>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>andreas fritsche</investigator_full_name>
    <investigator_title>Prof. Dr. med. Andreas Fritsche</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus type 2</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>lifestyle intervention</keyword>
  <keyword>body fat distribution</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

